首页> 外文OA文献 >Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer

【2h】

Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer

机译：I型病毒免疫治疗剂CanerpatureV（C-Rev）与Gemcitabine Plus Nab-Paclitaxel相结合的结果，作为无可切除的胰腺癌的一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Y. Hashimoto; S. Hijioka; Y. Hirooka; E. Ohno; T. Ioka; S. Kobayashi; T. Okusaka; Y. Maruki; J. Yashika; R. Ashida; J. Furuse; M. Ikeda; H. Kasuya; M. Tanaka; M. Ueno;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma [J] . Lin Shui, Ke Cheng, Xiaofen Li, BMC Cancer . 2020,第1期

机译：用于开放标签，单臂，相IB / II的研究方案，替代素蛋白，NAB-PABLITAXEL和GEMCITABINE的组合作为不可切除的胰腺导管腺癌患者的一线治疗
2. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study [J] . Chen Chang, Xiaofen Li, Dan Cao BMC Cancer . 2021,第1期

机译：吉西他滨，NAB-PABLITAXEL和S-1（天然气）作为局部晚期或晚期胰腺导管腺癌患者的一线治疗：开放标签的研究方案，我研究的单臂阶段
3. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). [J] . Masato Ozaka, Yuji Matsumura, Hiroshi Ishii, Cancer chemotherapy and pharmacology. . 2012,第5期

机译：吉西他滨和S-1组合与单独使用吉西他滨治疗不能切除的晚期胰腺癌的随机II期研究（日本临床癌症研究组织PC-01研究）。
4. Changing the treatment paradigm: Ex vivo assessment of gemcitabine-eluting degradable polymeric fibres for the treatment of pancreatic cancer [C] . Simon Moulton, Amanda Zuzic, Samantha Wade, World biomaterials congress . 2016

机译：改变治疗范式：吉西他滨洗脱可降解聚合物纤维的离体评估，用于治疗胰腺癌
5. Multiscale Pharmacodynamic Studies of Combination Gemcitabine and Trabectedin for the Treatment of Pancreatic Cancer. [D] . Miao, Xin. 2017

机译：吉西他滨联合曲贝汀联合治疗胰腺癌的多尺度药效学研究。
6. Study protocol for an open-label single-arm phase Ib/II study of combination of toripalimab nab-paclitaxel and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma [O] . Lin Shui, Ke Cheng, Xiaofen Li, 2020

机译：用于开放标签单臂相IB / II的研究方案替代素蛋白NAB-PABLITAXEL和GEMCITABINE的组合作为不可切除的胰腺导管腺癌患者的一线治疗
7. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma [O] . Lin Shui, Ke Cheng, Xiaofen Li, 2020

机译：用于开放标签，单臂，相IB / II的研究方案，替代素蛋白，NAB-PABLITAXEL和GEMCITABINE的组合作为不可切除的胰腺导管腺癌患者的一线治疗

Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer

著录项

引文网络

相似文献

相关主题

期刊订阅